… The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3…
overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban …

… Concentrations were compared to published reference values for non-obese patients.
Demographic, clinical, biological and therapeutic data were collected. Univariate and multivariate …

… patients, apixaban and rivaroxaban were not associated with an increased incidence of
treatment failure or major bleeding in MO patients… , apixaban and rivaroxaban may be safe to use …

… Rather than comparing DOACs to warfarin for NVAF in obesity, we compared non-obese
and obese patient groups. This strategy directly compares effectiveness and safety differences …

… of treatment assignment. Patients’ weight in each cohort was equal to the inverse of their
probability of receiving treatment with rivaroxaban (ie 1/PS for the rivaroxaban cohort and 1/[1-…

… the rivaroxaban group [29], [30]. This increase in major bleeding was seen in both the obese
… non-obese populations and it may be explained by the worse clinical profile of our patients …

… The evidence of rivaroxaban's pharmacokinetics in obese compared with non-obese …
We aimed to compare the pharmacokinetic profile of rivaroxaban between obese and non-obese …

… 2 1/2 years of patient follow-up, we found prescription of rivaroxaban to be associated with a
… reduction in major bleeding compared to warfarin in NVAF patients with a BMI ≥ 30 kg/m 2 . …

… rivaroxaban for obese patients with NVAF. Real-world observational data for inter-class
comparisons of DOACs for NVAF have been published in recent years, which include non-obese …

… of rivaroxaban versus warfarin in obese patients with venous … safety of rivaroxaban versus
warfarin in obese VTE patients. … Patients with a body mass index (BMI) ≥ 30 kg/m 2 admitted …